Parliament Workbench
Data: Motions & questions to 19 Nov 2026

Written Question · S4W-07082 · Session 4

Further to the answer to question S4W-06002 by Nicola Sturgeon on 8 March 2012, for what reason the draft quality performance indicators fo…

Answered Asked by Mary Scanlon Con Lodged 8 May 2012

The question

To ask the Scottish Executive, further to the answer to question S4W-06002 by Nicola Sturgeon on 8 March 2012, for what reason the draft quality performance indicators for prostate cancer do not include indicators relating to (a) active surveillance, (b) watchful waiting, (c) radiotherapy, (d) chemotherapy, (e) end-of-life care, (f) post-surgical sexual dysfunction, (g) access to clinical nurse specialists or (h) the provision of balanced information on the prostate-specific antigen (PSA) test for men at a higher risk of prostate cancer and whether it considers that the indicators are (i) comprehensive and (ii) provide a single reference point for (A) men with prostate cancer and (B) healthcare professionals.

The answer

Answered by Nicola Sturgeon on 16 May 2012 · 8 days after it was lodged, on time

Quality Performance Indicators (QPIs) are designed to measure and give an overall indication of the quality of a service. The prostate cancer QPIs are not intended to be all encompassing or a single reference point for either men with prostate cancer or healthcare professionals.
The National Cancer Quality Steering Group has an extensive work programme which aims to develop QPIs for all tumour types. For some tumour types this will include QPIs for chemotherapy and radiotherapy. In addition, it is developing generic QPIs which will be applicable to all tumour types. Under the auspices of the National Advisory Group for Palliative and End of Life care, QPIs are also being developed to cover this aspect, regardless of disease type.
With regards to balanced information on prostate specific antigen (PSA) testing this is available in the form of a Prostate Cancer Risk Management Pack which was issued to NHS boards and all general practitioners in Scotland in 2009. The programme provides guidance to medical practitioners on the situations in which it is suitable to offer PSA testing, the information and guidance that should be provided to patients before PSA testing is undertaken, and the support that may be required by men as they deal with the consequences of the PSA test and any resulting diagnosis. The Prostate Cancer Risk Management pack is available website at: http://www.scotland.gov.uk/Topics/Health/health/cancer/publications.
NHS inform was launched in 2010 which is a health information service to provide the public, patients and carers with a wide range of quality-assured health information online at www.nhsinform.co.uk. This includes information on cancer.

In the Official Report

No contribution in the Official Report cites S4W-07082 by reference.